Your SlideShare is downloading. ×
Microsoft Word - Final Asia Pacific VC Nov 1 07
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Microsoft Word - Final Asia Pacific VC Nov 1 07

447

Published on

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
447
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. TABLE OF CONTENTS FOREWORD ................................................................................................................................................... i ASIA PACIFIC VENTURE CAPITAL FIRMS ..................................................................................................... 1 INDEX OF VC FIRMS .................................................................................................................................. 69 INDEX OF CONTACT NAMES ....................................................................................................................... 72 INDEX OF VC FIRMS BY LOCATION ............................................................................................................ 77 INDEX OF VC FIRMS BY FOCUS .................................................................................................................. 81 INDEX OF BIOTECH COMPANIES INVESTED IN BY VC FIRMS ...................................................................... 83
  • 2. 2008 Biotechnology Venture Capital Directory FOREWORD BioAbility, a world leader in providing strategic business information in biotechnology and the life sciences, has developed a database of Asia Pacific venture capital (VC) firms that invest in biotechnology companies. The information from that database is presented here as a user-friendly directory. This is the first edition of the Asia Pacific Biotechnology VC Directory. BioAbility researched the Asia Pacific venture capital community via commercial databases, surveys, analysis of websites, country-specific venture capital associations, and direct contact with the firms. VC firms believed to be involved in biotechnology investment have been included in this directory. Firms that indicated a willingness to invest in biotechnology were included, even if none of their past investments have been in biotechnology. In some cases, these firms have multiple physical locations (sites), which are also included in this directory. This directory contains the following: • 241 VC sites of 101 VC firms • 472 contact names Please note that the definition of investing in “biotechnology” is taken very broadly and was self-defined by the venture capital firms when they were submitting information. Another criterion for inclusion was that the firm typically has a site in the Asia Pacific region, but does not have to be headquartered there. Thus, some of the firms in this directory have headquarters in the U.S. or Europe. Contact information for the headquarters location has been included for comprehensiveness. Biotechnology portfolios were determined for most of the 101 firms in this directory. Information on companies these firms invested in is presented with each VC firm in the main section of this directory. When available, the biotechnology portfolio is historical, containing not only active investments, but also biotechnology companies invested in previously, some of which are no longer in business. Further, an index of 565 biotechnology companies detailing their VC investors is presented at the end of this directory. The biotechnology companies listed may be located anywhere in the world. Also presented are an overall index of venture capital firms, an index of contact names, an index of areas of focus, and a listing of venture capital firm sites by country, further segmented by city. Note that some websites may not be able to be viewed by all web browsers. English-language versions of most of the websites are available. However, a few sites were only in Chinese and were directly translated for inclusion. We found that many faxes to Asia Pacific firms failed on one attempt, but were successful on a subsequent attempt. Fax transmission failure was typically due to problems such as all circuits being busy or poor line condition. Because Hong Kong is a special administrative region of China and maintains a degree of autonomy, it has been treated as a separate country for the purposes of this directory. The country names used in this directory are the widely recognized short forms of the names; for example, Singapore is used instead of Republic of Singapore. BioAbility has made every effort to compile data that is up-to-date and accurate. To help ensure accuracy, we requested feedback from each VC firm listed herein on the information we had collected. Firms were contacted up to three times, or as necessary, in order to verify accuracy. In cases where faxes were not transmitted successfully, we contacted the firms by email or telephone. However, not all VC firms responded, and not all firms update their online information regularly. Further, despite our efforts to be up-to-date, with over 470 contacts listed in this directory, it is likely that at any point, some will change position or change their contact information. BioAbility® and BioWorld® i
  • 3. 2008 Biotechnology Venture Capital Directory Location of Asia Pacific Biotech VC Sites In the Asia Pacific region, we identified the largest number of VC firms investing in biotechnology in China. For their size, both Singapore and Hong Kong stand out. These are both financial hubs, and Singapore in particular has worked to attract the biotech industry. In addition to the 221 sites distributed in the Asia Pacific region as shown below, this directory includes 17 sites in the U.S., two in the UK, and one in Germany. Those sites are included because they are the headquarters locations for firms that invest in, and typically have offices in, the Asia Pacific region. Asia Pacific VC Sites by Country Asia Pacific VC Sites by Country Rank Country Count Rank Country Count Australia 14 1 China 57 China 57 2 India 34 Hong Kong 21 3 Singapore 27 India 34 4 Hong Kong 21 Indonesia 1 4 Japan 21 Japan 21 6 Taiwan 15 Malaysia 8 7 Australia 14 New Zealand 9 8 New Zealand 9 Pakistan 1 8 South Korea 9 Philippines 1 10 Malaysia 8 Singapore 27 11 Thailand 2 South Korea 9 12 Indonesia 1 Taiwan 15 12 Pakistan 1 Thailand 2 12 Philippines 1 Vietnam 1 12 Vietnam 1 Acknowledgements This directory was created by BioAbility and published by BioWorld. Data collection and verification were undertaken by Mark Chang, with assistance by Chengsi Huang and Jessica Lunsford. Data collection was facilitated by the Mandarin fluency of both Chang and Huang. The directory was edited by Melanie C. Trull with support from Tracey V. du Laney, Neal R. Clegg and Victoria W. Smith. This project was managed by BioAbility’s president, Mark D. Dibner. ® ® ii BioAbility and BioWorld
  • 4. 2008 Biotechnology Venture Capital Directory ASIA PACIFIC VENTURE CAPITAL FIRMS 3i Group plc Headquarters 2i Capital Private Ltd. 16 Palace Street London, United Kingdom SW1E 5JD 613 Oxford Towers Phone: +44 2079283131 139 Airport Road Fax: +44 2079280058 Bangalore, India 560008 Web: www.3i.com Phone: +91 8041151990 Fax: +91 8041151994 Contacts Web: www.2icapital.com Buisson, Nicole E-mail: info@2icapital.com Business Development Manager, Europe Contacts Chaya, Dina Sekhar, Vivek Director Principal Jassal, Ramesh Kamath, Sudhir Healthcare Analyst Managing Director Lobley, Ian Singh, Shailesh Senior Partner Vice President, Investments Lowery, Stephen Chandra, Vijay Director Assistant Vice President, Investments China Raja, Vinutha Assistant Vice President, Investments 3i plc - Beijing Office Unit 01, 25/F, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing, China 100004 Phone: +86 1065352888 Fax: +86 1065058731 Web: www.3i.com E-mail: beijing@3i.com Contact Orchard, Dominic Director, Business Development Asia 3i plc - Shanghai Office Unit 3908, 39/F, The Center 989 ChangLe Road Shanghai, China 200031 Phone: +86 2154076188 Fax: +86 2154076088 Web: www.3i.com Contact Orchard, Dominic Director, Business Development Asia BioAbility® and BioWorld® 1
  • 5. 2008 Biotechnology Venture Capital Directory 3i Group plc (continued) 3V SourceOne Capital LLC Hong Kong Headquarters 3i plc - Hong Kong Office 1 Coleman Street, No. 06-05 Singapore, Singapore 179803 Suite 1903 19/F Two International Finance Centre Phone: +65 63381880 8 Finance Street, Central Fax: +65 63380086 Hong Kong Web: www.3vs1.com Phone: +852 29018188 E-mail: 3V@3vs1.com Fax: +852 25377886 Web: www.3i.com Contacts Tan, Kim Seng Contact General Partner Orchard, Dominic Director, Business Development Asia Khoo, Jeffrey General Partner India See, Gerald Associate 3i plc - Mumbai Office Ng, Bee In 3rd Floor, Nicholas Piramal Tower Manager, Finance and Admin Peninsula Park, Ganpatrao Kadam Marg Lower Parel (West) Mumbai, Maharashtra, India 400013 Phone: +91 2266523131 China Fax: +91 2266523141 Web: www.3i.com 3V SourceOne Capital LLC - Shanghai Office 5/G Hua Min Empire Plaza No. 726, Yan An Road West Singapore Shanghai, China 200050 Phone: +86 2162516032 3i plc - Singapore Office Web: www.3vs1.com 80 Raffles Place, No. 33-20 UOB Plaza 2 Singapore, Singapore 048624 Contacts Phone: +65 64383131 Lim, Yew Seng Fax: +65 65362429 Venture Partner Web: www.3i.com Ip, KK Biotechnology Portfolio Venture Partner Amaxa Biosystems AG; Amphora Discovery Corporation; Domantis Ltd.; Doxa AB; Elbion NV; Biotechnology Portfolio EUSA Pharmaceuticals Inc.; Evotec AG; Idea AG; ChemNavigator Inc.; Intracel Holdings Corporation; Immatics Biotechnologies GmbH; Jerini AG; Newron Linden Bioscience; Omeros Corporation; Viacell Inc. Pharmaceuticals S.p.A.; Novexel Inc.; Paion AG; Small Bone Innovations Inc. Stages Funded Seed, Series A-B, Series C-D Stages Funded Seed, Series A-B 2 BioAbility® and BioWorld®

×